Laser bioprinting device and in vivo applications Laser bioprinting device and in vivo applications
- Coordinator
- Phosprint Anonymi Etaireia, Greece
- Runs
- 1 May 2023 to 30 April 2026
- Status
- Running
- EU funding
- €2.0m
- Total cost
- €2.9m
- Partners
- 1 organisations in 1 countries
- Type
- European Innovation Council
- Grant agreement
- 190195672
What the project is doing
In the project's own words, from its summary on CORDIS.
PhosPrint's D-LIB platform technology is based on a compact and automated laser bioprinter and protocols for high-speed and high-precision in-vivo printing of tissues with autologous human body characteristics. The bioprinter relies on the Laser Induced Forward Transfer (LIFT) technique to accomplish highly accurate and cost-effective printing of tissues. The bioprinter system is associated with protocols for cell isolation from autologous biopsies, cell expansion in-vitro, and cell printing in-vivo.
This is a truly new approach that allows for real-time tissue engineering/repair in complex medical conditions. D-LIB capabilities will enable the introduction of a laser bioprinting technology in surgery operations, starting with enterocystoplasty/augmentation in cystectomy bladder cancer patients as the selected go-to-market application.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Phosprint Anonymi Etaireia | Agia Paraskevi Athina | Greece | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI